Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval

 
• By Jessica Merrill
  
CMC issues were sited in the CRL, which can be resolved, Ultragenyx said. (Shutterstock)

More from Complete Response Letters

More from United States